Proposed Senate Amendment to Improve Critical Drug Shortage Notific…

The Frame

What this does

If enacted, this amendment would change the reporting requirements for pharmaceutical companies, potentially increasing the visibility of drug supply chain vulnerabilities for the Department of Defense and public health officials.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Drug Manufacturers

They must comply with new, more frequent reporting requirements for supply chain sources and provide earlier notifications for potential drug shortages.

Department of Defense

They will receive direct notifications from the Secretary of Health and Human Services whenever a manufacturer reports a potential drug supply disruption.

Physician and Patient Organizations

They are designated recipients of information distributed by the Secretary regarding drug shortages and supply disruptions.

What changed

Last recorded activity June 24, 2026.

What's next

Next step not available in the current record.

Summary

Senate Amendment 6294, proposed by Senator Amy Klobuchar, would update federal law to require drug manufacturers to provide earlier and more detailed notifications to the government regarding potential shortages of critical, life-saving medications. The amendment also mandates that manufacturers report their supply chain sources for active ingredients twice a year.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What drugs are considered 'covered drugs' under this proposal?

Covered drugs are those intended for human use that are life-supporting, life-sustaining, or used to prevent or treat debilitating diseases, including those critical during public health emergencies.

How often do manufacturers have to report their supply chain information?

Under the proposed amendment, manufacturers would be required to report their active pharmaceutical ingredient suppliers twice a year, specifically in March and September.

What happens if a manufacturer cannot provide 6 months' notice of a drug shortage?

If 6 months' notice is not possible, the manufacturer must provide notice as soon as practicable, or no later than 10 business days after the onset of the supply issue.

Why It Matters

If enacted, this amendment would change the reporting requirements for pharmaceutical companies, potentially increasing the visibility of drug supply chain vulnerabilities for the Department of Defense and public health officials.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Related Legislation

congressional_record

Senate Scheduling Update for S. 4784

The Senate has agreed to delay the vote on a cloture motion for S. 4784 until after the confirmation vote for the Schwartz nomination. This procedural

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift95% confidence

Increased Supply Chain Oversight

The amendment shifts from annual reporting to bi-annual reporting of supply chain sources, indicating a move toward more granular oversight of pharmaceutical manufacturing inputs.

Department of Health and Human Services

Connected Entities

personAmy Klobuchar“U.S. Senator who submitted the amendment.”Map →

organizationDepartment of Defense“The agency to be notified by the Secretary of Health and Human Services regardin”Map →

organizationDepartment of Energy“Mentioned in the context of the underlying bill S. 4784.”Map →

organizationGovernment Publishing Office“Publisher of the Congressional Record.”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance75
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Proposed Senate Amendment to Improve Critical Drug Shortage Notifications